Navigation Links
Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
Date:2/10/2010

essed or implied by any forward-looking statements include the risk that blinatumomab does not demonstrate safety and/or efficacy in future clinical trials, the risk that we will not obtain approval to market blinatumomab and the risks associated with reliance on outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2009, filed with the SEC on November 6, 2009, as well as other filings by the company with the SEC.

References:

1. American Cancer Society. Cancer Facts and Figures 2009.

2. Raff et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment.  Blood. 2007109: 910-915

SOURCE Micromet, Inc.

RELATED LINKS
http://www.micromet-inc.com

'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
2. Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
3. Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009
4. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
7. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
8. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
9. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
10. Micromet Key Events for 2009
11. Micromet Expands Committed Equity Financing Facility to $75 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 About ... artificial implants used to replace, augment, or repair ... a wide range of applications including cosmetic, spinal, ... are made of different materials such as polymers, ... the global implantable medical devices market to grow ...
(Date:9/2/2015)... , Sept. 2, 2015 Advanced Wound ... Summary Advanced dressings have steadily replaced traditional ... a variety of wound indications, such as trauma ... infection control, and physical protection become increasingly critical ... role in standard therapy. This report focuses ...
(Date:9/2/2015)... About Duchenne muscular dystrophy Duchenne ... affects the male population. It is characterized by ... caused due to mutations in the dystrophin gene, ... dystrophin (a protein essential for maintaining healthy muscle ... muscle function, causes loss of ambulation, harms the ...
Breaking Medicine Technology:Global Implantable Medical Devices Market 2015-2019 2Advanced Wound Dressings - SA Analysis and Market Forecasts 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3
(Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... In ... featured by the Huffington Post on August 25th, writer Akela Stanfield detailed her lifelong ... While the author acknowledged that she had always seen herself as someone who would ...
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , ... launch of its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced ... prescriber usability. A leader in health technology, RxNT was one of the first ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... announces its latest addition to its screen mirroring and extending product line -- ... Wireless Display, which operates in local WIFI setting, the new Splashtop Wired XDisplay ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... goods, intermediate or final products. Automating sample handling makes density measurements more efficient ... showing each step of the automated workflow and the advantages compared to manual ...
(Date:9/2/2015)... ... 02, 2015 , ... Good health and a good cause paired up at ... (Horizon BCBSNJ) donated $11,000 to the New Jersey Golf Foundation through its Healthy Steps ... of The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer and NJ native Morgan Hoffmann ...
Breaking Medicine News(10 mins):Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3
... Center have developed an assay that may be used ... predisposition to cancer. , The study, published in the ... in yeast and mammalian cells. , Cancer cells show ... Schiestl, have discovered a mechanism that switches on that ...
... SAN DIEGO, March 25 ADVENTRX Pharmaceuticals, Inc. (NYSE ... has granted Shin Poong Pharmaceutical Co., Ltd. (SEO: 019170.KS) ... sell ANX-514 (docetaxel emulsion), one of its two lead ... ADVENTRX will receive an upfront cash payment of $300,000, ...
... health system in vanguard of electronic medical ... 25 In a major stride towards ... signed an agreement with MobileMD to implement ... Access (EA) technologies and services. PinnacleHealth will ...
... Effect Ensures Maximum Value from Pharmacy ProgramsMILWAUKEE, March ... and Gorman Health Group announced a joint offering ... provide comprehensive drug benefit oversight. Gorman Health ... firm, is integrating TRICAST,s advanced pharmacy claims analysis ...
... ImQuest Life Sciences presented their latest biological results ... pyrimidinedione inhibitors of HIV-1 at the Prevention of ... highlighted new data supporting the selection of lead ... to the selection of drug resistant virus strains ...
... interaction with cyclosporine could lead to fatal complications ... People taking the immunosuppressant cyclosporine should avoid consuming ... and possibly lead to deadly consequences, new research ... rats taking cyclosporine -- commonly used to help ...
Cached Medicine News:Health News:Discovery may result in new test to determine predisposition to cancer 2Health News:Discovery may result in new test to determine predisposition to cancer 3Health News:ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea 2Health News:ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea 3Health News:ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea 4Health News:PinnacleHealth Selects MobileMD for Health Information Exchange Service 2Health News:PinnacleHealth Selects MobileMD for Health Information Exchange Service 3Health News:TRICAST, Inc. and Gorman Health Group Form Partnership to Fully Support Medicare Part D Oversight 2Health News:TRICAST, Inc. and Gorman Health Group Form Partnership to Fully Support Medicare Part D Oversight 3Health News:ImQuest Presentations at Keystone Symposium Focus on Advancements in Their Therapeutic and Microbicide Development Programs 2Health News:Licorice May Block Absorption of Organ Transplant Drug 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: